Elanix Biotechnologies

We are a tissue regeneration company dedicated to using innovative cell technologies, advancing patient wound care and healing processes

Elanix develops and markets progenitor cell-based products to help regenerate tissue and promote healing in the treatment of burns, gynecological and dermatological conditions. The Company is headquartered in Berlin, Germany with offices in Nyon, Canton Vaud, Switzerland and Wiesbaden, Germany, and listed on the Frankfurt stock exchange under the symbol ELN.

BUSINESS UPDATE

A message from Tomas J. Svoboda, CEO

I wanted to take a few moments to provide a business update for our valued shareholders.

Here at Elanix Biotechnologies, our mission is to help save and improve lives through the power of cells and their derivatives. We are dedicated to …

SCIENTIFIC RATIONALE

Progenitor cells are fully differentiated yet immunologically neutral cells that are very potent inducers of tissue growth and healing. Elanix enhances the activity of progenitor cells with proprietary cytokine formulations to create unique cell therapy products and procedures.

MARKETED PRODUCTS & PIPELINE

Elanix owns two specialty cosmetics , GYNrepair® and SKINrepair®, marketed in Switzerland since 2012 in gynecology and dermatology.

Elanix is developing a bioresorbable & bioactive skin dressing derived from progenitor skin fibroblasts to accelerate regeneration and improve quality of skin following acute burns.

PARTNERS

BioReliance
EasyWell
goetzpartners
SINCOPHARM

NEWS